Literature DB >> 17858795

The Use of Testosterone Propionate in the Treatment of Advanced Carcinoma of the Breast.

F E Adair, J B Herrmann.   

Abstract

Entities:  

Year:  1946        PMID： 17858795      PMCID： PMC1803552     

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  21 in total

1.  Hypercalcemia in carcinoma of the breast.

Authors:  A G JESSIMAN; K EMERSON; R C SHAH; F D MOORE
Journal:  Ann Surg       Date:  1963-03       Impact factor: 12.969

2.  An evaluation of adrenalectomy in man: physiological changes and the effect on advanced neoplastic disease.

Authors:  H T RANDALL
Journal:  Bull N Y Acad Med       Date:  1954-04

Review 3.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

4.  Testosterone propionate in the treatment of pulmonary metastases from breast carcinoma; report of a case.

Authors:  A KLASS
Journal:  Can Med Assoc J       Date:  1948-01       Impact factor: 8.262

5.  The Carcinogenic and Carcinostatic Effects of Estrogens on Breast Tissue.

Authors:  M Fremont-Smith
Journal:  Trans Am Clin Climatol Assoc       Date:  1946

6.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

Review 7.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

8.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat.

Authors:  S Li; X Yan; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.